Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Rheumatology Women's Health Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Clinical Trial Active — Not Recruiting Phase I NCT06478420

COVID-19 Omicron BA.5 Subvariant Dose Finding Infection Study

COVID-19 Omicron BA.5 Subvariant Dose Finding Infection Study — Active Not Recruiting • Phase I • Infectious Disease • NCT06478420.

📅 24 Apr 2026 ⏱ 1 min read
Active — Not Recruiting
Check the registry for current status and eligibility criteria.
Status
Active — Not Recruiting
Phase
Phase I
NCT ID
NCT06478420
Start
2024-08-08
Completion
2028-10-31
ClinicaliQ Trial Snapshot
  • COVID-19 Omicron BA.5 Subvariant Dose Finding Infection Study — Active Not Recruiting • Phase I • Infectious Disease • NCT06478420.
  • Researchers tested different doses of Omicron BA.5 virus in vaccinated volunteers to find the optimal dose for future COVID vaccine studies.

Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

A phase 1, dose-finding open label clinical infection, safety and viral detection optimization in healthy volunteers immunologically experienced against SARS-CoV-2. Conditions: SARS-CoV-2 Infection Interventions: Omicron BA.5 SARS-CoV-2 challenge virus Lead Sponsor: University of Oxford Planned Enrollment: 45 participants

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Clinical Brief
Vaccines a huge success, but public trust must be earned – key findings from Covid report
Infectious Disease · BBC Health · 16 Apr 2026
COVID-19 vaccination programmes demonstrated substantial public health impact, preventing hundreds of thousands of deaths across the UK population Vaccine hesitancy persists as…
View brief →
Clinical Brief
Vaccines a huge success, but public trust must be earned – key findings from Covid report
Infectious Disease · BBC Health · 16 Apr 2026
COVID-19 vaccination programmes prevented hundreds of thousands of deaths in the UK, demonstrating the substantial public health impact of immunisation strategies during…
View brief →
Clinical Brief
Covid inquiry PPE report – key findings
Infectious Disease · BBC Health · 14 Jul 2026
COVID Inquiry PPE Report - Clinical Practice Takeaways Government failed to maintain adequate PPE stockpiles before the pandemic despite previous recommendations, leaving…
View brief →
Clinical Brief
UK wasted £10bn on PPE that left NHS staff poorly protected, Covid inquiry finds
Infectious Disease · BBC Health · 14 Jul 2026
NHS staff faced inadequate personal protective equipment (PPE) during the pandemic despite £10bn expenditure, leaving them vulnerable to infection and potentially compromising…
View brief →
Clinical Brief
What is the UK Covid inquiry and how does it work?
Infectious Disease · BBC Health · 16 Apr 2026
The UK Covid inquiry's fourth report acknowledges the national vaccination programme as an "extraordinary feat" of public health delivery during the pandemic.…
View brief →
Clinical Brief
First person gets new experimental vaccine for Ebola
Infectious Disease · BBC Health · 24 Jul 2026
A new experimental Ebola vaccine has entered human trials, with a UK volunteer as the first recipient, representing progress toward preventing this…
View brief →